<?xml version="1.0" encoding="UTF-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
  <title>Opinion Health - Latest Health News</title>
  <link href="http://opinionhealth.co.uk/mediawatch.atom.xml" rel="self"/>
  <link href="http://opinionhealth.co.uk/" rel="alternate"/>
  <link href="http://opinionhealth.co.uk/mediawatch.rss.xml" rel="self" type="application/rss+xml"/>
  <id>http://opinionhealth.co.uk/</id>
  <updated>2010-03-11T08:27:07Z</updated>
  <author>
    <name>Opinion Health</name>
  </author>
  <entry>
    <title>FDA will review Fosamax, Boniva for safety</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4840"/>
    <id>http://opinionhealth.co.uk/r/4840</id>
    <updated>2010-03-11T08:27:07Z</updated>
    <summary>The Food and Drug Administration said [on] Wednesday it's conducting a safety review of certain bone-building drugs like Fosamax and Boniva to see if they increase the risk of femur fractures.</summary>
  </entry>
  <entry>
    <title>FDA rejects Actelion's Zavesca for rare NP-C disease </title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4839"/>
    <id>http://opinionhealth.co.uk/r/4839</id>
    <updated>2010-03-11T08:26:35Z</updated>
    <summary>Actelion&#8217;s bid to get a new use approved for Gaucher disease drug Zavesca has suffered a setback after regulators in the USA asked more information on the drug as a treatment for a rarer condition.</summary>
  </entry>
  <entry>
    <title>FDA panel backs InterMune's Esbriet for IPF </title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4837"/>
    <id>http://opinionhealth.co.uk/r/4837</id>
    <updated>2010-03-11T08:26:13Z</updated>
    <summary>Shares in InterMune will soar today after advisors to the US Food and Drug Administration voted in favour of recommending Esbriet for approval as a treatment for lung scarring.</summary>
  </entry>
  <entry>
    <title>C&amp;W wins diabetes work</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4836"/>
    <id>http://opinionhealth.co.uk/r/4836</id>
    <updated>2010-03-11T08:25:44Z</updated>
    <summary>Merck Sharp &amp; Dohme has selected Cohn &amp; Wolfe to handle the PR for its type two diabetes treatment, Januvia, after a competitive pitch. The brief is believed to be worth &#163;1m and will be headed by C&amp;W's London healthcare team.</summary>
  </entry>
  <entry>
    <title>Porter Novelli snares former Hill &amp; Knowlton healthcare boss Shipra </title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4835"/>
    <id>http://opinionhealth.co.uk/r/4835</id>
    <updated>2010-03-11T08:25:28Z</updated>
    <summary>Porter Novelli has signed former Hill &amp; Knowlton healthcare chief Shipra Singh to head its EMEA healthcare business.</summary>
  </entry>
  <entry>
    <title>Ark considers bids after failure of brain tumour drug trial</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4833"/>
    <id>http://opinionhealth.co.uk/r/4833</id>
    <updated>2010-03-11T08:25:10Z</updated>
    <author>The Independent</author>
    <summary>Ark Therapeutics, the AIM-listed pharmaceuticals group, said yesterday that it would consider offers for the company after its potential brain cancer treatment, Cerepro, was rejected by European regulators</summary>
  </entry>
  <entry>
    <title>Abbott to acquire Facet Biotech</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4830"/>
    <id>http://opinionhealth.co.uk/r/4830</id>
    <updated>2010-03-11T08:24:37Z</updated>
    <author>PMLive</author>
    <summary>Abbott is to acquire Californian-based Facet Biotech in a deal valued at approximately $722m.</summary>
  </entry>
  <entry>
    <title>Botox approved for upper limb spasticity</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4829"/>
    <id>http://opinionhealth.co.uk/r/4829</id>
    <updated>2010-03-11T08:23:35Z</updated>
    <author>PMLive</author>
    <summary>Allergan has announced that the US FDA has approved Botox (onabotulinumtoxinA) for the treatment of increased elbow, wrist and finger muscle stiffness in adults with upper limb spasticity.</summary>
  </entry>
  <entry>
    <title>Teva appoints Dr Phillip Frost as chair</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4828"/>
    <id>http://opinionhealth.co.uk/r/4828</id>
    <updated>2010-03-11T08:23:03Z</updated>
    <author>PMLive</author>
    <summary>Israeli generics manufacturer, Teva has announced the appointment of Dr Phillip Frost to the role of chairman of the Board of Directors.</summary>
  </entry>
  <entry>
    <title>Time for drug giants to jump into the patent pool?</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4827"/>
    <id>http://opinionhealth.co.uk/r/4827</id>
    <updated>2010-03-11T08:21:27Z</updated>
    <author>The Guardian</author>
    <summary>While drugmaking giant GlaxoSmithKline has picked up a load of good press for CEO Andrew Witty's developing world initiatives - from ploughing back some of the (tiny) profits made in Africa to the more interesting patent pool it announced for neglected tropical diseases - it is Californian rival Gilead that gets a higher approval rating at the moment from Aids campaigners.</summary>
  </entry>
  <entry>
    <title>Low diagnostic yield of elective coronary angiography</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4826"/>
    <id>http://opinionhealth.co.uk/r/4826</id>
    <updated>2010-03-11T08:21:02Z</updated>
    <author>New England Journal of Medicine</author>
    <summary>Background - Guidelines for triaging patients for cardiac catheterisation recommend a risk assessment and noninvasive testing.</summary>
  </entry>
  <entry>
    <title>Diabetes injection Byetta LAR faces Food and Drug Administration decision</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4825"/>
    <id>http://opinionhealth.co.uk/r/4825</id>
    <updated>2010-03-11T08:20:38Z</updated>
    <summary>Following clinical trials, considerable investment and a great deal of anticipation the long-action version of diabetes drug Byetta now faces an approval decision by the [US] Food and Drug Administration.</summary>
  </entry>
  <entry>
    <title>Doctors 'failing to give correct cholesterol targets'</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4824"/>
    <id>http://opinionhealth.co.uk/r/4824</id>
    <updated>2010-03-11T08:20:18Z</updated>
    <author>BBC</author>
    <summary>Many lives could be saved if GPs followed guidelines for reducing cholesterol in patients at high risk of heart disease, research suggests.</summary>
  </entry>
  <entry>
    <title>Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4823"/>
    <id>http://opinionhealth.co.uk/r/4823</id>
    <updated>2010-03-10T08:29:44Z</updated>
    <author>BMJ</author>
    <summary>Objectives - To examine the relation between health and several dimensions of sexuality and to estimate years of sexually active life across sex and health groups in middle aged and older adults.</summary>
  </entry>
  <entry>
    <title>Virus can attack prostate cancer</title>
    <link type="text/html" rel="alternate" href="http://opinionhealth.co.uk/r/4822"/>
    <id>http://opinionhealth.co.uk/r/4822</id>
    <updated>2010-03-10T08:29:29Z</updated>
    <author>CBC</author>
    <summary>Researchers in Alberta have successfully tested a new viral approach to treating prostate cancer in a small number of men.</summary>
  </entry>
</feed>
